Table 4.
Multivariate analyses of various clinical parameters in prostate cancer patients
| Parameters | According to optimal cut-off values | According to clinical reference values | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival | Cancer-Specific Survival | Overall Survival | Progression-Free Survival | Cancer-Specific Survival | Overall Survival | |||||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | 0.096 | - | - | - | - | - | 0.440 | - | - | - | - | |
| Gleason Score | ||||||||||||
| ≤7 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| >7 | 1.703(1.265-2.293) | <0.001 | 2.890(1.687-4.951) | <0.001 | 2.468(1.574-3.870) | <0.001 | 1.699(1.261-2.288) | <0.001 | 2.888(1.682-4.959) | <0.001 | 2.464(1.568-3.872) | <0.001 |
| Metastasis | ||||||||||||
| No | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Yes | 3.236(2.398-4.368) | <0.001 | 6.156(3.433-11.039) | <0.001 | 3.546(2.276-5.526) | <0.001 | 3.420(2.538-4.608) | <0.001 | 6.916(3.873-12.351) | <0.001 | 3.893(2.510-6.039) | <0.001 |
| AFPG | ||||||||||||
| Grade 1 | 2.601(1.758-3.847) | <0.001 | 4.014(2.204-7.309) | <0.001 | 3.406(2.024-5.729) | <0.001 | 3.061(1.330-7.046) | 0.009 | 4.178(1.640-10.648) | 0.003 | 3.738(1.480-9.440) | 0.005 |
| Grade 2 | 1.306(0.954-1.789) | 0.096 | 1.717(0.989-2.971) | 0.055 | 1.449(0.907-2.314) | 0.120 | 1.930(1.393-2.673) | <0.001 | 2.223(1.407-3.514) | 0.001 | 1.939(1.276-2.945) | 0.002 |
| Grade 3 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Abbreviations: HR: hazard ratio; CI: confidence interval; PSA: prostate-specific antigen; AFPG: pretreatment albumin and fibrinogen combined prognostic grade.